Details.
Provides assistance for Combivir, Cabenuva, Dovato, Epivir, Epzicom, Juluca, Lexiva, Retrovir, Rukobia, Selzentry, Tivicay and Tivicay PD, Triumeq and Triumeq PD, Trizivir, Viracept, and Ziagen. Financial eligibility is 500% FPL. Additional insurance and prescription coverage requirements may apply. ViiVConnect stopped accepting new applications in July 2022 for certain products listed in the publication.